Display options
Cite
Ashur-Fabian O, Zloto O, Fabian I, et al. Tetrac Delayed the Onset of Ocular Melanoma in an Orthotopic Mouse Model. Front Endocrinol (Lausanne). 2019;9:775doi: 10.3389/fendo.2018.00775.
Ashur-Fabian, O., Zloto, O., Fabian, I., Tsarfaty, G., Ellis, M., Steinberg, D. M., Hercbergs, A., Davis, P. J., & Fabian, I. D. (2018). Tetrac Delayed the Onset of Ocular Melanoma in an Orthotopic Mouse Model. Frontiers in endocrinology, 9775. https://doi.org/10.3389/fendo.2018.00775
Ashur-Fabian, Osnat, et al. "Tetrac Delayed the Onset of Ocular Melanoma in an Orthotopic Mouse Model." Frontiers in endocrinology vol. 9 (2018): 775. doi: https://doi.org/10.3389/fendo.2018.00775
Ashur-Fabian O, Zloto O, Fabian I, Tsarfaty G, Ellis M, Steinberg DM, Hercbergs A, Davis PJ, Fabian ID. Tetrac Delayed the Onset of Ocular Melanoma in an Orthotopic Mouse Model. Front Endocrinol (Lausanne). 2019 Jan 08;9:775. doi: 10.3389/fendo.2018.00775. eCollection 2018. PMID: 30671022; PMCID: PMC6331424.
Copy Download .nbib Format: NLM
Share it on

Front Endocrinol (Lausanne). 2019 Jan 08;9:775. doi: 10.3389/fendo.2018.00775. eCollection 2018.

Tetrac Delayed the Onset of Ocular Melanoma in an Orthotopic Mouse Model.

Frontiers in endocrinology

Osnat Ashur-Fabian, Ofira Zloto, Ina Fabian, Galya Tsarfaty, Martin Ellis, David M Steinberg, Aleck Hercbergs, Paul J Davis, Ido Didi Fabian

Affiliations

  1. Department of Human Molecular Genetics and Biochemistry, The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  2. Translational Hemato-Oncology Laboratory, Meir Medical Center, The Hematology Institute and Blood Bank, Kfar-Saba, Israel.
  3. Goldschleger Eye Institute, Sheba Medical Center, Affiliated to The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  4. Department of Cell and Developmental Biology, The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  5. Department of Diagnostic Imaging, Sheba Medical Center, Ramat Gan, Israel.
  6. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  7. Department of Statistics and Operations Research, Tel Aviv University, Tel Aviv, Israel.
  8. Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH, United States.
  9. Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, United States.
  10. Department of Medicine, Albany Medical College, Albany, NY, United States.

PMID: 30671022 PMCID: PMC6331424 DOI: 10.3389/fendo.2018.00775

Abstract

Ocular melanoma research, the most common primary intraocular malignancy in adults, is hindered by limited

Keywords: melanoma; mouse; tetrac; thyroid; αvβ3 integrin

References

  1. Curr Eye Res. 1999 Feb;18(2):125-9 - PubMed
  2. Melanoma Res. 2000 Feb;10(1):2-8 - PubMed
  3. Br J Ophthalmol. 2001 Jun;85(6):732-8 - PubMed
  4. Endocrinology. 2004 Jul;145(7):3265-72 - PubMed
  5. Invest Ophthalmol Vis Sci. 2004 Jul;45(7):2056-64 - PubMed
  6. Mol Biol Cell. 2005 Apr;16(4):1901-12 - PubMed
  7. Endocrinology. 2005 Jul;146(7):2864-71 - PubMed
  8. Arch Ophthalmol. 2005 Dec;123(12):1639-43 - PubMed
  9. Curr Eye Res. 2006 Jun;31(6):557-62 - PubMed
  10. Cancer Res. 2006 Jul 15;66(14):7270-5 - PubMed
  11. Int Angiol. 2006 Dec;25(4):407-13 - PubMed
  12. Steroids. 2007 Feb;72(2):180-7 - PubMed
  13. Thyroid. 2008 Feb;18(2):239-53 - PubMed
  14. J Endocrinol. 2008 Mar;196(3):509-17 - PubMed
  15. Arch Ophthalmol. 2008 Oct;126(10):1413-8 - PubMed
  16. Am J Ophthalmol. 2009 Jul;148(1):119-27 - PubMed
  17. Invest Ophthalmol Vis Sci. 2010 Jan;51(1):28-34 - PubMed
  18. Cell Cycle. 2009 Nov 1;8(21):3562-70 - PubMed
  19. Nat Rev Cancer. 2010 Jan;10(1):9-22 - PubMed
  20. Endocr Rev. 2010 Apr;31(2):139-70 - PubMed
  21. Curr Opin Endocrinol Diabetes Obes. 2010 Oct;17(5):432-6 - PubMed
  22. J Immunol. 2010 Sep 15;185(6):3481-8 - PubMed
  23. Br J Ophthalmol. 2011 Jan;95(1):112-7 - PubMed
  24. Annu Rev Pharmacol Toxicol. 2011;51:99-115 - PubMed
  25. Invest Ophthalmol Vis Sci. 2011 Apr 01;52(5):2662-8 - PubMed
  26. Invest Ophthalmol Vis Sci. 1990 Feb;31(2):247-57 - PubMed
  27. Ophthalmology. 2011 Sep;118(9):1881-5 - PubMed
  28. Oncogene. 2012 Mar 1;31(9):1105-16 - PubMed
  29. Mol Cancer Res. 2011 Oct;9(10):1385-94 - PubMed
  30. J Biomed Biotechnol. 2012;2012:959057 - PubMed
  31. J Control Release. 2012 Dec 10;164(2):213-20 - PubMed
  32. Ocul Surf. 2012 Oct;10(4):251-63 - PubMed
  33. Endocr Relat Cancer. 2013 Mar 22;20(2):R19-29 - PubMed
  34. Prog Retin Eye Res. 2013 May;34:89-124 - PubMed
  35. Mol Pharm. 2013 Oct 7;10(10):3603-11 - PubMed
  36. Thyroid. 2013 Dec;23(12):1503-9 - PubMed
  37. Cancer Med. 2013 Oct;2(5):674-86 - PubMed
  38. Leuk Lymphoma. 2015 Apr;56(4):1107-14 - PubMed
  39. Oncotarget. 2014 Aug 15;5(15):6312-22 - PubMed
  40. Front Endocrinol (Lausanne). 2015 Jan 12;5:240 - PubMed
  41. Oncotarget. 2015 May 10;6(13):11038-46 - PubMed
  42. Oncol Rep. 2015 Jun;33(6):2737-45 - PubMed
  43. Oncotarget. 2015 Jun 20;6(17):14735-43 - PubMed
  44. Oncogene. 2016 Apr 14;35(15):1977-87 - PubMed
  45. Nat Rev Endocrinol. 2016 Feb;12(2):111-21 - PubMed
  46. Ocul Oncol Pathol. 2015 Apr;1(3):141-50 - PubMed
  47. J Control Release. 2016 Aug 10;235:1-13 - PubMed
  48. Mol Cell Endocrinol. 2017 Dec 15;458:76-81 - PubMed
  49. Invest Ophthalmol Vis Sci. 1987 Sep;28(9):1599-604 - PubMed
  50. Endocrinology. 1984 Jul;115(1):95-101 - PubMed
  51. Invest Ophthalmol Vis Sci. 1984 Sep;25(9):1080-6 - PubMed
  52. Curr Eye Res. 1995 May;14(5):399-404 - PubMed
  53. Invasion Metastasis. 1994-1995;14(1-6):349-61 - PubMed
  54. Cancer Lett. 1994 Oct 14;85(2):189-94 - PubMed
  55. Arch Ophthalmol. 1996 Sep;114(9):1116-20 - PubMed

Publication Types